Abstract

BackgroundMalaria continues to impose a tremendous burden in terms of global morbidity and mortality, yet even today, a large number of diagnoses are presumptive resulting in lack of or inappropriate treatment.MethodsIn this work, a two-colour lateral flow immunoassay (LFA) system was developed to identify infections by Plasmodium spp. and differentiate Plasmodium falciparum infection from the other three human malaria species (Plasmodium vivax, Plasmodium ovale, Plasmodium malariae). To achieve this goal, red and blue colours were encoded to two markers on a single test line of strips, for simultaneous detection of PfHRP2 (red), a marker specific for P. falciparum infection, and pLDH (blue), a pan-specific marker for infections by all species of Plasmodium. The assay performance was first optimized and evaluated with recombinant malarial proteins spiked in washing buffer at various concentrations from 0 to 1000 ng mL−1. The colour profiles developed on the single test line were discriminated and quantified: colour types corresponded to malaria protein species; colour intensities represented protein concentration levels.ResultsThe limit of detection (the lowest concentrations of malaria antigens that can be distinguished from blank samples) and the limit of colour discrimination (the limit to differentiate pLDH from PfHRP2) were defined for the two-colour assay from the spiked buffer test, and the two limits were 31.2 ng mL−1 and 7.8 ng mL−1, respectively. To further validate the efficacy of the assay, 25 human whole blood frozen samples were tested and successfully validated against ELISA and microscopy results: 15 samples showed malaria negative; 5 samples showed P. falciparum positive; 5 samples showed P. falciparum negative, but contained other malaria species.ConclusionsThe assay provides a simple method to quickly identify and differentiate infection by different malarial parasites at the point-of-need and overcome the physical limitations of traditional LFAs, improving the multiplexing potential for simultaneous detection of various biomarkers.

Highlights

  • Malaria continues to impose a tremendous burden in terms of global morbidity and mortality, yet even today, a large number of diagnoses are presumptive resulting in lack of or inappropriate treatment

  • These antibodies will bind to malaria antigens, such as parasite lactate dehydrogenase, Plasmodium falciparum histidine-rich protein2 (PfHRP2), and parasite aldolase [7, 8]

  • The concurrent detection of PfHRP2 and parasite lactate dehydrogenase (pLDH) allows the discrimination of P. falciparum infection from the other three human malaria species (i.e., P. vivax, P. ovale, P. malariae)

Read more

Summary

Introduction

Malaria continues to impose a tremendous burden in terms of global morbidity and mortality, yet even today, a large number of diagnoses are presumptive resulting in lack of or inappropriate treatment. Despite increasing malaria control measures, malaria infection remains a global threat for millions of children, especially for those in sub-Saharan Africa [3]. Most RDTs for malaria diagnosis are based on a lateral flow immunoassay (LFA), with pre-coated antibodies on test lines. These antibodies will bind to malaria antigens, such as parasite lactate dehydrogenase (pLDH), Plasmodium falciparum histidine-rich protein (PfHRP2), and parasite aldolase (pAldo) [7, 8]. PfHRP2 detection is specific to P. falciparum only, and pLDH pan-specific to all Plasmodium species. The concurrent detection of PfHRP2 and pLDH allows the discrimination of P. falciparum infection from the other three human malaria species (i.e., P. vivax, P. ovale, P. malariae)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call